Increasing heart dose is linked to poorer overall survival (OS) and cardiac toxicity in patients with locally advanced non-small cell lung cancer (NSCLC) treated with chemoradiation, according to a retrospective study (J Thorac Oncol 2016 Oct 12. [Epub ahead of print], PMID: 27743888).
“We have identified that increasing heart dose is an independent dosimetric predictor of worse OS, even after accounting for well-established patient- and tumor-related predictors of OS,” the authors